Integrated Whole-Genome Analysis of Hematologic Disorders

This study is currently recruiting participants.

Verified May 2012 by Stanford University

First Received on April 19, 2010. Last Updated on May 10, 2012 History of Changes

Sponsor:	Stanford University
Information provided by (Responsible Party):	Stanford University
ClinicalTrials.gov Identifier:	NCT01108159

Purpose

To identify mutations, changes in DNA copy number, structural rearrangements, or altered microRNA/mRNA expression that are important for the initiation, progression, or treatment response of hematologic disorders.

Condition	Intervention
Hematologic Diseases	Procedure: Blood Draw Procedure: Skin Biopsy

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Integrated Whole-Genome Analysis of Hematologic Disorders Using High-Throughput Sequencing and Array Technologies

Resource links provided by NLM:

Genetics Home Reference related topics: Help Me Understand Genetics

U.S. FDA Resources

Further study details as provided by Stanford University:

Biospecimen Retention: Samples With DNA

blood, bone marrow, skin biopsy

Estimated Enrollment:	100
Study Start Date:	September 2009
Estimated Primary Completion Date:	December 2017 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

participants with hematologic disorders

Criteria

Inclusion Criteria:

18 years of age or older
Patient meets the clinical and/or pathologic criteria for the hematologic disorder being examined.
Patient is willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.

Exclusion Criteria:

Less than 18 years of age
Patient is not willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01108159

Contacts

Contact: Jason D Merker

(650) 922-1885

jdmerker@stanford.edu

Locations

United States, California
Stanford University School of Medicine	Recruiting
Stanford, California, United States, 94305
Contact: Jason D Merker 650-922-1885 jdmerker@stanford.edu
Contact: Cancer Clinical Trials Office (650) 498-7061
Principal Investigator: James L Zehnder
Sub-Investigator: Scott Boyd
Sub-Investigator: Athena M. Cherry
Sub-Investigator: Andrew Fire
Sub-Investigator: Jason Robert Gotlib
Sub-Investigator: Eleanor L. Marshall
Sub-Investigator: Jason Merker
Sub-Investigator: Stephen Tracy Oh

Sponsors and Collaborators

Stanford University

Investigators

Principal Investigator:

James L Zehnder

Stanford University

More Information

No publications provided

Responsible Party:	Stanford University
ClinicalTrials.gov Identifier:	NCT01108159 History of Changes
Other Study ID Numbers:	HEM0013, 1081737-100-DHAAT, SU-09092009-3820
Study First Received:	April 19, 2010
Last Updated:	May 10, 2012
Health Authority:	United States: Institutional Review Board

Additional relevant MeSH terms:

Hematologic Diseases

ClinicalTrials.gov processed this record on May 24, 2012